Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 73

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 73
---
 spikes (from food) and crashes, fueling cravings. However, CB2 may counteract this cycle of increased dopamine demand by reducing neuroinflammation that sensitizes reward pathways. Chronic stress and obesity-related inflammation, whether in the brain, gut, or adipose tissue, further intensify cravings. CB2 helps by calming immune cells like microglia and macrophages, while CB1 may worsen stress signaling. In the gut, CB1 promotes hunger via ghrelin and vagal signals; CB2 reduces the inflammatory exaggeration of these cues. MAO-B in adipose tissue or liver may influence energy signals back to the brain. In obesity, CB1-driven hedonic eating dominates. High MAO-B may blunt dopamine’s satiety signal, while low CB2 allows inflammation to amplify stress-eating. CB1 drives hunger and fat storage; MAO-B weakens satiety by clearing dopamine; CB2 may stabilize this system via anti-inflammatory effects. Together, these pathways form a feedback loop that reinforces overeating, especially under stress or inflammation.

Source: SKNY Pharmaceuticals, Inc.

Tetrahydrocannabivarin (THCV) as a Solution

In recent years, the cannabis plant has emerged as a surprising ally in the battle against weight gain, with certain strains showing promise for weight management. Among these, Tetrahydrocannabivarin (“THCV”), a compound found in cannabis has been gaining attention as “nature’s Ozempic,” due to its potential in aiding weight loss and managing appetite

THCV, a compound found in cannabis, differs from THC in its effects on appetite and metabolism. Unlike THC, which is known to stimulate appetite, THCV has been observed to decrease appetite and increase energy metabolism in rodent models. This unique property of THCV presents an intriguing option for weight management andthe treatment of obesity and diabetes. (Source: British Journal of Pharmacology )

In lower doses, studies have proved that THCV acts as a CB1 antagonist and a CB2 partial agonist. As an antagonist, THCV blocks the action of cannabinoids at the CB1 receptor, especially in the central nervous system. This action is crucial because CB1 receptors are widely implicated in appetite regulation and feeding behavior. By blocking CB1 receptors, THCV can potentially reduce hunger and prevent overeating. In higher doses, it may start to activate CB1 receptors, albeit less intensely than THC. This dual action makes THCV an interesting subject for research in appetite control and weight management